TITLE

FDA Submissions, Approvals & Other Actions: April 2013

PUB. DATE
May 2013
SOURCE
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p27
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A table is presented on the U.S. Food and Drug Administration (FDA) submissions, approvals & other actions as of April, 2013 which lists pharmaceutical products of several pharmaceutical companies including CytRx Corp., Durect Corp., and Tris Pharma Inc.
ACCESSION #
87619299

 

Related Articles

  • New Products.  // Drug Topics;Feb2010, Vol. 154 Issue 2, p44 

    The article offers updates related to drugs in the U.S. The Food and Drug Administration (FDA) has approved Clonidine ER suspension and Clonidine ER tablets from Tris Pharma. Sandoz Pharmaceutical Corp. has introduced the calcipotriene solution 0.005%. Eli Lilly & Co. revealed that the FDA has...

  • GENERICS NEWSLINE.  // Monthly Prescribing Reference;Oct2012, Vol. 28 Issue 10, pA-12 

    The article offers news briefs related to generic drugs as of September 19, 2012. Watson Inc. has announced the U.S. Food and Drug Administration's (FDA's) approval of their Abbreviated New Drug Application (ANDA) for Lidocaine Topical Patch 5%, generic version of Endo Pharmaceuticals' Lidoderm....

  • Pain Therapeutics, Durect Drop 30%+ After Remoxy CRL. Wall, Tom // BioWorld Today;6/27/2011, Vol. 22 Issue 123, p1 

    The article reports on the impact of a U.S. Food and Drug Administration (FDA) complete response letter (CRL) on Pfizer's resubmission of the new drug application (NDA) for Remoxy on the share prices of Pain Therapeutics Inc. and Durect Corp. Pfizer also lost 57 cents to close at 20.08 U.S....

  • Other News To Note.  // BioWorld Today;4/17/2013, Vol. 24 Issue 73, p3 

    This section offers news briefs on the pharmaceutical industry. California-based Durect Corp. has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for Posidure, a postoperative pain relief depot. Immunovaccine Inc. of Nova Scotia, Canada has received 407,700...

  • FDA Approvals In April.  // BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p7 

    A table is presented which lists pharmaceutical companies and their drugs which have been approved by the U.S. Food and Drug Administration (FDA) including Sitavig manufactured by BioAlliance Pharma SA, Amitiza by Sucampo Pharmaceuticals Inc., and Karbinal ER by Tris Pharma Inc. in April, 2013.

  • News Briefs.  // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1499 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new formulation of docetaxel and a needleless intravenous (i.v.) connector with chlorhexidine and silver and zero-fluid displacement.

  • Slew of approvables.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p27 

    Lists several approval drugs by the U.S. Food and Drug Administration. Ranexa to treat chronic angina; Insulin determir, a long-acting form of the diabetes drug; Fortament, an extended-release product to lower blood glucose.

  • FDA actions in brief.  // Formulary;Feb2010, Vol. 45 Issue 2, p42 

    The article discusses news briefs about drugs approved by the U.S. Food and Drug Administration (FDA). The drugs include dalfampridine extended release tablets, tocilzumab and morphine sulfate oral solution.

  • Pipeline preview.  // Formulary;Apr2010, Vol. 45 Issue 4, p113 

    The article offers U.S. Food & Drug Administration (FDA) drug approval news briefs. Miglustat has been approved for the treatment of Niemann-Pick type C disease, pirfenidone has been recommended for approval to improve lung function and pixantrone has been recommended not to be approved.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics